Saturday 17 October 2026
Export IONS’s income statement to Excel — free account
Ionis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024. In the quarter to June 2026, revenue fell 40.7%, EPS fell 188.5%, free cash flow grew 299.3% and total debt rose 116.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
42.94
1.18
−2.67%
Follow IONS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
15.01 | 11.70 | 13.41 | 10.81 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
23.19 | (15.62) | (91.92) | (79.52) | |
P/B ratio |
29.83 | 25.19 | 25.88 | 16.91 | |
Price to Tangible BV |
31.98 | 26.81 | 27.55 | 17.76 | |
EV/Sales |
14.69 | 11.57 | 12.46 | 9.15 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(25.87) | (13.44) | (43.79) | (35.84) | |
EV/FCF |
(22.63) | (12.52) | (36.11) | (28.60) | |
Quick Ratio |
6.70 | 2.78 | 3.51 | 2.51 | |
Current Ratio |
7.89 | 4.10 | 3.83 | 2.79 | |
Net Debt/EBITDA |
7.31 | 5.01 | 4.26 | 10.33 | |
Debt/Assets |
45.12% | 39.11% | 50.50% | 19.65% | |
Debt/Equity |
3.07 | 2.75 | 3.64 | 0.96 | |
Asset Turnover |
0.29 | 0.34 | 0.29 | 0.32 | |
Operating CF/Net income |
(4.93) | 8.57 | 0.60 | 1.02 | |
Capex/Depreciation |
(2.99) | (6.45) | (6.23) | (6.48) | |
Interest Coverage |
(4.62) | (5.22) | (9.45) | (7.23) | |
Research and Development Expense of Revenue |
81.03% | 85.40% | 137.53% | 138.95% | |
Selling, General and Administrative Expense of Revenue |
56.13% | 61.10% | 64.03% | 61.77% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
17.02% | 17.58% | 21.31% | 19.87% | |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.36%) | (2.65%) | (2.98%) | (2.46%) | |
Free Cash Flow Yield |
(4.33%) | (7.90%) | (2.57%) | (2.96%) | |
Revenue per Share |
1.62 | 1.49 | 1.27 | 0.98 | |
Operating CF per Share |
3.42 | (4.81) | (0.86) | (0.82) | |
Capex per Share |
(0.11) | (0.14) | (0.14) | (0.04) | |
Free Cash Flow per Share |
3.31 | (4.95) | (1.00) | (0.87) | |
Cash per Share |
12.42 | 11.64 | 16.73 | 14.02 | |
Shareholders Equity per Share |
2.66 | 2.98 | 3.06 | 3.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.66 | 2.98 | 3.06 | 3.87 | |
Free Cash Flow |
547.30 | (816.07) | (160.37) | (138.37) | |
Working Capital |
2,175.64 | 2,220.35 | 2,209.07 | 1,615.54 | |
Capital Expenditures |
(18.23) | (23.25) | (22.66) | (6.93) | |
Net Current Asset Value |
(63.49) | (21.61) | (44.11) | 103.87 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.07 | 0.09 | 0.11 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
55.71 | 56.70 | 79.12 | 21.27 | |
Average Payables |
35.25 | 21.74 | 35.52 | 11.69 | |
Average Inventory |
29.66 | 8.53 | 11.28 | 19.46 | |
Average Assets |
2,989.82 | 3,131.46 | 3,263.76 | 3,057.10 | |
Average Common Equity |
535.73 | 483.57 | 538.72 | 640.22 |
Columns are period end dates